Insilico Designing of a Chimeric Vaccine Using EIS (Rv2416c) Protein Against Mycobacterium Tuberculosis H37Rv; An Immunoinformatics Approach

Logesh Radhakrishnan  
B S Abdur Rahman Crescent Institute of Science & Technology

Lavanya V  
Guru Nanak College

Shazia Jamal  
B S Abdur Rahman Crescent Institute of Science & Technology

Neesar Ahmed (✉ neesar.sls@crescent.education)  
B S Abdur Rahman Crescent Institute of Science & Technology  https://orcid.org/0000-0002-7367-2188

Research Article

Keywords: H37Rv, EIS, Vaccine, immunoinformatic

DOI: https://doi.org/10.21203/rs.3.rs-733350/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Mycobacterium tuberculosis (Mt) is a respiratory pathogen that causes Tuberculosis disease (TB). There are a large number of proteins that are involved in the pathogenesis of TB. Stimulating the immune response against TB is very important to clear the pathogens from host. In the present study, an Immunoinformatics conduit is used for epitope based chimeric vaccine designing against TB. Enhanced Intracellular Survival (EIS) protein from Mt is used for designing the chimeric vaccine. 1 B-cell epitope, 8 cytotoxic T lymphocyte (CTL) and 6 Helper T lymphocyte (HTL) epitopes were predicted based on the MHC allele binding, immunogenicity, antigenicity, allergenicity, toxicity and IFN epitopes. The selected epitopes were used for chimeric vaccine designing. Further, 3D structure elucidation, structural refinement and validation of the designed chimeric vaccine was carried out. The 3D structure was used for Protein-Protein docking studies with Toll like receptor 4 (TLR-4), followed by molecular dynamic simulation (MDS) and the interaction between the chimeric vaccine and TLR-4 complex was verified.

Introduction

Tuberculosis (TB) is a chronic infectious disease that is caused by the respiratory pathogen, Mycobacterium tuberculosis (Mt). According to the WHO report, worldwide about 10 million people are known to be affected by TB every year [1]. Further, among the global causes of death, TB is ranked among the top 10. The highest rate of infection occur in countries such as Indonesia, Philippines, Afghanistan, Bolivia and Peru. New cases are also identified in densely populated nations such as China and India. Isoniazid, pyrazinamide, rifampicin and ethambutol are the first-line antituberculosis drugs[2]. Control and treatment of TB is greatly hindered by development of multidrug-resistance TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Thus, new drugs are being constantly developed to control the spread of MDR-TB and XDR-TB. Ethylsulfonyl benzodiazaborine (AN12855) is one such compound that was shown to bind to and inhibit the enoyl-ACP reductase (InhA)[3]. The efficacy of AN12855 has also been established in vivo in C3HeB/FeJ mouse model that showed caseous nectrotic lung lesions, wherein, the compound exhibited remarkable potential against isoniazid-resistant strains of Mt[4]. Treatment with a combination of drugssuch as pretomanid, linezolid and bedaquiline also showed promise in treatment of patients with XDR-TB[5].

Progression of TB is associated with the host response to Mt infection. The innate immune cells including the macrophages, dendritic cells and the natural cells play a key role in determining the course of infection as they are the first to confront the Mt pathogen, upon infection [6]. Once the disease progresses, the active T cells (CD4+ and CD8+) move to the lungs and interact with the antigen presenting cells. Cytokines including interleukins, IFN-γ, and TNF-α play important role in the immune response against TB[7, 8]. In the early stage of infection, host innate immune responses like reactive nitrogen intermediates play key role [9]. The role of B cells and humoral immunity in the early immune response against the Mt pathogen cannot be overlooked[10]. The B cells are also known to modulate the T cells through various mechanisms, resulting in shaping of immune response against the Mt pathogen[11, 12]. Both CD4+ CD8+ subsets of T cells play a key role in immunological response against Mt infection.
In an animal model, during the early stage of infection, CD4+ and CD8+ T cells were found to migrate into the lungs, thereby increasing the host immune response [14]. Upon infection, the macrophages are known to identify the Mtb through the toll like receptors (TLR, most commonly TLR-2 and TLR-4) that leads to phagocytosis and control of Mtb pathogen. Further, the macrophage secret interleukin-12 (IL-12) resulting in the production of interferon-γ (IFN-γ) by the T cells[15]. Interleukins including IL-2, IL-1β, IL-6, IL-10, IL-12 and chemokines are also involved in the host immune resistance to Mtb pathogen[16, 17]. However, Mtb keeps evolving to successfully modulate and evade the immune responses [18]. Certain mycobacterial components expressed by the Mtb have been shown to inhibit the production of TNF, thereby evading the host immune response [19]. Stimulating the immune response against TB is very important to clear the pathogens from the host. There are a large number of proteins involved in the pathogenesis of TB. One of the secretory protein from Mtb is the Enhanced Intracellular Survival (EIS) protein that plays multiple functions in the pathogenesis of TB[20]. The EIS protein from Mtb is a 42 kDa cytoplasmic secretory protein involved in progression, activation and immune response during the macrophage infection. EIS is a hexomeric form of aminoglycoside acetyltransferase enzyme that has the capacity to inhibit the activities of second line TB drugs like aminoglycoside antibiotics, through multi-acetylation mechanism[21, 22]. EIS was also shown to aid in the survival of Mtb by modulating the secretion of IL-10 and TNF-α[23, 24].

Immunoinformatics is an interface between computational biology and experimental immunology. It involves analysis of biological information using statistical techniques and computer. It acts as the platform to understand the immunological information through the computational methods and resources[25]. Immunoinformatics is a new subclass of bioinformatics with variety of different approaches and tools to analysis the immunological data. It involves using different methods and tools to understand the immune response and immune system against pathogens, thereby aiding in accelerating the progression of immunological research[26]. In the present study, insilico approach has been applied to design a chimeric vaccine against TB, incorporating the EIS gene from Mtb. Initially, the B cell, cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) epitopes were predicted. The antigenicity, allergenicity, toxicity and the IFN-inducing ability of the predicted epitopes were evaluated. Subsequently, highly antigenic, non-allergenic and non-toxic B-cell, CTL and HTL epitopes were selected for construction of the chimeric vaccine. To increase the immune response, 50S ribosomal protein Rv0652 from Mtb H37Rv was used as an adjuvant. The physiochemical properties such as molecular-weight, theoretical isoelectric point (pI), instability index, aliphatic index, grand average hydropathicity (GRAVY), hydrophobicity and hydrophilicity were determined using the ProtScale and ProtParam tools from ExPASy. After the tertiary structure of the chimeric vaccine was predicted, refined and validated, the interaction between the constructed chimeric vaccine with TLR-4 was evaluated by molecular docking studies. During Mtb infection, increased expression of TLR-4 in host immune cells are observed. Thus, to corroborate the host immune response that develops as a result of interaction between the immune cells and Mtb, TLR-4 was chosen as the immune receptor. Finally, molecular dynamic simulation of the chimeric vaccine (EISvac) with immune receptor was performed to determine if the interaction between the ligand and the receptor are stable.
Materials And Methods

Sequence retrieval

FASTA format of the EIS protein amino acid sequence from H37Rv Mtb strain was extracted from Mycobrowser (https://mycobrowser.epfl.ch/genes/Rv2416c). The structures of EIS (4JD6) and TLR-4 (4G8A) were downloaded from the Protein Data Bank (PDB).

Prediction of B-cell epitopes

B-cell epitope prediction was done using the IEDB (Immune Epitope DataBase and analysis resource) server. The linear B-cell epitopes were predicted based on the accessibility, flexibility, hydrophilicity and antigenicity of the B-cells[27]. Emini’s method was used for surface accessibility prediction and Karplus and Schulz’s algorithm was used for flexibility determination [28, 29]. The method of kolaskar and tongaonkar was used for antigenicity prediction [30]. Further, to predict the hydrophilicity, the method proposed by parker et al., was used [31]. Conformational B-cell epitopes were predicted using the Epitope prediction based upon structural protrusion (ElliPro) tool from IEDB (http://tools.iedb.org/ellipro/) [32].

Cytotoxic T-lymphocyte (CTL) epitopes and immunogenicity prediction

CTL epitopes were predicted using the IEDB MHC-I tool (http://tools.iedb.org/mhci/). The FASTA sequence of EIS protein was used for CTL epitope prediction. This server predicts CD8+ T cell epitopes based on the proteasomal C terminal cleavage, MHC-I binding and TAP transport efficiency. IEDB MHC-I tool predicts the proteasomal C terminal cleavage, MHC-I binding and TAP transport efficiency using weight matrix, artificial neural networks and IC50 value. The epitopes were predicted for the human alleles (HLA-A*01:01, HLA-A*01:01, HLA-A*02:01, HLA-A*02:01, HLA-A*02:03, HLA-A*02:03, HLA-A*02:06, HLA-A*02:06, HLA-A*03:01, HLA-A*03:01, HLA-A*11:01, HLA-A*11:01, HLA-A*23:01, HLA-A*23:01, HLA-A*24:02, HLA-A*24:02, HLA-A*26:01, HLA-A*26:01, HLA-A*30:01, HLA-A*30:01, HLA-A*30:01, HLA-A*30:02, HLA-A*30:02, HLA-A*31:01, HLA-A*31:01, HLA-A*32:01, HLA-A*32:01, HLA-A*33:01, HLA-A*33:01, HLA-A*68:01, HLA-A*68:01, HLA-A*68:02, HLA-A*68:02, HLA-B*07:02, HLA-B*07:02, HLA-B*08:01, HLA-B*08:01, HLA-B*08:01, HLA-B*15:01, HLA-B*15:01, HLA-B*15:01, HLA-B*35:01, HLA-B*35:01, HLA-B*40:01, HLA-B*40:01, HLA-B*44:02, HLA-B*44:02, HLA-B*44:03, HLA-B*44:03, HLA-B*51:01, HLA-B*51:01, HLA-B*53:01, HLA-B*53:01, HLA-B*57:01, HLA-B*57:01, HLA-B*58:01, HLA-B*58:01, HLA-B*58:01). The epitopes with IC50 value less than 50 were selected for further studies [33, 34]. Immunogenicity of the predicted CTL epitopes were analyzed using the IEDB class I Immunogenicity prediction tool (http://tools.iedb.org/immunogenicity/) and highly immunogenic CTL epitopes were used for further studies [35].

Helper T lymphocyte (HTL) epitopes prediction

HTL epitopes were predicted using MHC2Pred tool from Raghava online bioinformatic tools (http://crdd.osdd.net/raghava/mhc2pred/index.html). In this tool HTL epitopes were predicted based on
the MHC-II allele binding, using SVM support Vector Machine algorithms. FASTA format of the protein sequence was submitted to the server and default parameters were applied[36, 37].

**Antigenicity and allergenicity prediction**

For Antigenicity prediction, conformational B-cell epitope, CTL epitopes and HTCepitopeamino acid sequences were submitted to the VaxiJen v2.0 server tool from pharmfac server (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) and highly antigenic epitopes were selected for further analysis[38]. Allergenicity of the B-cell, CTL and HTL epitopes were predicted using freely available allergenicity prediction tool (http://www.ddg-pharmfac.net/AllerTOP/index.html) AllerTOPv. 2.0. AllerTOPv. 2.0 predicts the allergens based on the machine learning methods like auto and cross covariance transformation, k nearest neighbors and amino acid E-descriptors[39].

**Toxicity and IFN-γ inducing epitope prediction**

Toxicity of the B-cell, CTL and HTL epitopes were predicted using the freely available toolToxinPred (http://crdd.osdd.net/raghava/toxinpred/). This tool utilizes the quantitative matrix properties of the peptide and machine learning methods to predict the toxicity of the peptides. The advantage of this tool is that it also predicts the physiochemical properties of the epitopes[40]. The IFN-γ inducing epitopes from B-cell, CTL and HTL epitopes were predicted using the IFN-γ inducing epitopes predicting and designing tool(https://webs.iiitd.edu.in/raghava/ifnepitope/predict.php). This tool works based on motif, support vector machine and hybrid approach to predict the IFN-γ inducing epitopes[41, 42].

**Designing of the chimeric vaccine (EISvac)**

To design the chimeric vaccine, highly antigenic, non-allergenic and non-toxic B-cellepitopes, CTL epitopes and HTL epitopes were selected. For increasing the immune response, 50S ribosomal protein Rv0652 from Mtb H37Rv was used as adjuvant. EAAAK, AAY and GPGPG were the peptide linkers used for linking different epitopes[43, 44].

**Tertiary structure prediction and Refinement of the chimeric vaccine (EISvac)**

The 3D structure of the chimeric vaccine was predicted using the RaptorX server tool. FASTA format of the chimeric vaccine construct was submitted to the server (http://raptorx.uchicago.edu/)[45, 46]. After the tertiary structure of the vaccine was predicted, the structure was refined using the 3Drefine server tool, The highly ranked model was submitted(http://sysbio.rnet.missouri.edu/3Drefine/index.html)[47].

**Tertiary Structural validation of chimeric vaccine (EISvac)**

Tertiary structural validation is a process to detect the errors in the predicted 3D model of the vaccine constructs. 3D structure validation was done using different, freely available structure validation tools like PROCHECK from SAVEv 5.0, ERRAT server and ProSA-web[48]. ERRAT server was used to identify the overall quality factor of the 3D model[49]. ProSA-web is a web server to detect the overall quality and
Evaluation of Physiochemical properties of chimeric vaccine (EISvac)

Physiochemical properties like molecular weight, number of amino acids, number of nucleobases, theoretical pI, instability index, aliphatic index, grand average hydropathicity (GRAVY), hydrophobicity and hydrophilicity of the amino acids were evaluated using freely available bioinformatic servers like ProtScale and ProtParam from ExPASy [51–53].

Molecular Docking of the chimeric vaccine (EISvac) with the immune receptor

It is important to know the predicted chimeric vaccine's interaction with the immune receptor and whether the construct will generate the immune response. Thus, molecular docking between the EISvac (ligand) and TLR-4 (receptor) was performed using ZDOCK model from Discovery Studio client 2017. Default parameters were set and angular step size was set as 15 [54–56].

Molecular Dynamic Simulation (MDS) of the chimeric vaccine (EISvac) with Immune receptor

MDS was performed to know the physical basis of the protein structure and function of the biological macromolecules. MDS for the chimeric vaccine (EISvac), TLR-4 and the complex (TLR-4 with EISvac) was performed using Discovery Studio client 2017, CHARMM force-field was applied to determine the intramolecular interaction and stability. To remove the high energy configuration of the macromolecules, energy minimization step was performed. The MDS was performed at a temperature of 300K for 0.4ns. To determine the standard deviation and protein backbone fluctuation, the trajectory analysis was run and root mean square deviation (RMSD) and root mean square fluctuation (RMSF) were obtained. Overall, five step MDS run was conducted. The steps were followed by minimization one and two, heating, equilibration and production [57, 58].

Results And Discussion

Primary analysis of the sequenceretrieved from Mycobrowser

The chimeric vaccine was constructed using the EIS protein sequence from Mtb H37Rv strain. The FASTA sequence and structure of the protein were retrieved from Mycobrowser and Protein Data Bank, respectively. Immunoinformatics analysis were used to predict the antigenicity and allergenicity of the protein. The EIS protein was predicted as a probable antigen (0.5344) and non-allergen. Further, B cell, CTL and HTL epitopes were predicted using FASTA sequence of the EIS protein.

B-cell epitope prediction
B-cell epitopes were predicted using the ElliPro tool from IEDB server. The epitopes were predicted based on the properties of B cell epitopes like surface accessibility, surface antigenicity, surface flexibility and surface hydrophilicity (Fig. 1a-d). In the ElliPro server, epitopes were predicted based on the tertiary structure of the protein. The sequences of the 42 B cell epitope epitopes that were predicted are mentioned in Table 1.

**Prediction of CTL epitopes and immunogenicity**

From the EIS protein sequence, CTL epitopes were predicted using the MHC-I tool from IEDB server. This server predicts the epitopes based on the MHC-I allele binding, proteasomal C terminal cleavage and TAP transport efficiency. From the IEDB server, reference allele set was selected for epitope prediction. Around 87 epitopes were predicted based on the MHC-I allele binding and IC50 value less than 50 (Supplementary material Table S1). Immunogenicity for all 87 epitopes were also predicted using class I immunogenicity prediction tool from IEDB server.

**Helper T lymphocyte (HTL) epitopes prediction**

HTL epitopes were predicted from EIS protein using MHC2Pred tool from Raghava server tool. Epitopes were predicted based on the MHC-II binding and top rank score epitope from each MHC-II allele was shortlisted. In all, 41 HTL epitopes were predicted based on the top score and MHC-II allele binding (Table S2).

**Antigenicity and allergenicity prediction**

The amino acid sequences of the predicted 42 B-cell epitopes, 87 CTL epitopes and 41 HTL epitopes were submitted in the VaxiJen v2.0 server tool to predict the antigenicity. The B-cell epitope with the highest antigenic nature was selected for further studies (Table 1). The CTL epitopes and the HTL epitopes that showed antigenicity score of more than 0.6 were selected for further studies. From the 87 CTL epitopes, 13 epitopes (Table 2) and out of the 41 T Helper cell epitopes, 14 epitopes (Table 3) were thus selected. The short listed epitope sequences of B-cell, CTL and HTL were submitted to AllerTOPv 2.0 server tool to predict the allergenicity of the epitopes.

**Toxicity and IFN-γ inducing epitope prediction**

IFN-γ is a key cytokine that plays a pivotal role in host defense against bacterial pathogens including Mtb, through various mechanisms [59, 60]. Thus, after predicting the antigenicity and allergenicity, the final shortlisted B-cell, CTL and HTL epitope sequences were submitted to tools that predict the non-toxic and IFN-γ inducing epitopes. For toxicity prediction, ToxinPred tool was used. Those sequences that are non-toxic are shown in Table 4. Only 5 positive epitopes that can induce IFN-γ production were identified by the IFN-γ inducing epitope prediction tool (Table 4).

**Designing of chimeric Vaccine (EISvac)**
For the chimeric vaccine (EISvac) construction, epitopes that were highly antigenic, non-allergenic and non-toxic, and some that were capable of inducing IFN-γ production were selected. Accordingly, one B-cell epitope, 8 CTL epitopes and 6 HTL epitopes were selected (Table 4). The selected epitopes were linked with amino acid linkers like EAAAK, GPGPG and AAY. Further, to increase the immune response, 50S ribosomal protein Rv0652 was added as an adjuvant to the N-terminal end of the vaccine. The amino acid sequence of the constructed chimeric vaccine is mentioned in Table 5.

**Tertiary structure prediction and refinement of chimeric vaccine (EISvac)**

The tertiary structure of the chimeric vaccine was predicted using the RaptorX protein structure prediction tool. RaptorX is a web-based server that does not require any template to predict the secondary and tertiary structure of proteins [61]. Five best models were generated after the amino acids sequence of the designed EISvac complex was submitted to RaptorX. The top ranked model from RaptorX was subjected to further refinement using the 3Drefine tool. Refinement of the initial, best models by the 3Drefine server generated five best models. Based on the scores of all the refined models, one model was used for structure validation (Fig. 2).

**Tertiary structural validation of chimeric vaccine (EISvac)**

Further analysis of the selected model by Ramachandran plot analysis revealed that 89.2% residues were in the most favoured regions, 9.0% residues were in additional allowed regions, 1.4% residues were in generously allowed regions and 0.4% residues were in disallowed regions (Fig. 3a). The overall quality of the model was substantiated by PROCHECK and ERRAT from SAVEv 5.0. The overall quality factor of the model after refinement with ERRAT was 98.476 (Fig. 3b) and the Z-score of this model as predicted by ProSA-web was -7.0 (Fig. 3c).

**Evaluation of Physiochemical properties of chimeric vaccine (EISvac)**

Based on the 3D refined models, favorable regions from Ramachandran plot and ERRAT results, the first model was selected for molecular docking and dynamic simulation. Physiochemical properties of chimeric vaccine (EISvac) were predicted using ProtScale and ProtParam from ExPASy (Table 6). The molecular weight of the chimeric vaccine was 34.8 kDa and the theoretical pI of the construct was found to be 6.52. The total number of the amino acids were 336 and the number of nucleobase was 1008. The instability index of the chimeric vaccine was evaluated to be 21.81, which denotes that the constructed vaccine is stable in nature. The aliphatic index of the vaccine was found to be 82.50 and indicates that the construct (EISvac) is thermostable. Hydropathicity of the vaccine (EISvac) was predicted by the ProtScale server Tool from ExPASy. The positive value denotes that those amino acid residues are hydrophobic and will not interact with water molecules while negative value denotes that the residues are hydrophobic (Fig. 3d). The grand average hydropathicity (GRAVY) of the chimeric vaccine was 0.001. The positive value denotes that the molecule is hydrophobic and will not interact with water molecules, thereby, it can be delivered using liposome modules.
Molecular Docking of the chimeric vaccine (EISvac) with the immune receptor

After validation of the 3D refined model of final chimeric vaccine construct (EISvac), it was deemed important to know the interaction of vaccine construct with TLR-4. Molecular docking studies between the TLR-4 and chimeric vaccine was performed using Discovery Studio client 2017. From the best docked 2000 poses obtained from the docking server, the top ranked and lowest ZRank score pose was selected for interaction and simulation studies. Accordingly, pose 1 for which docking rank was 1 and ZRank score was -124.008 was used for further studies. The structure of pose 1 obtained from PDB was visualized in surface mode using Discovery Studio client 2017 (Fig. 4). Around 33 interactions were identified between the construct (EISvac) and the TLR-4. Among the interactions, 8 carbon hydrogen Bonds, 9 conventional hydrogen bonds, 6 hydrophobic interactions (4 alkyl & 2 Pi-Alkyl), 7 electrostatic interaction and 3 salt bridge were identified. All the interactions and bond distances are mentioned in the Table 7.

Molecular dynamic simulation (MDS) of the chimeric vaccine (EISvac) with the immune receptor, TLR-4

Five step MDS of EISvac vaccine, TLR-4 and TLR-4-EISvac complex was done using Discovery studio client 2017. CHARMM Forcefield was applied for energy minimization and other steps. The overall energy minimization for the chimeric vaccine construct, TLR-4 and the complex (TLR-4+EISvac) are mentioned in the Supplementary material Tables S3, S4 and S5, respectively. In dynamic Simulation, during production step the potential energy was found to be-17495.972 kcal/mol for EISvac (Table S3), -90849.87 kcal/mol for TLR-4 (Table S4) and the potential energy of the complex was -109207.19 kcal/mol (Table S5). The Total energy of the ligand EISvac during the start of equilibration step was -13654.464 kcal/mol and decreased to -13845.511 kcal/mol at the end (Fig. 5a). Likewise, the total energy of TLR-4 decreased from -71400.23 kcal/mol to -73143.87 kcal/mol (Fig. 5b) and the total energy of the complex (TLR-4+EISvac) decreased from -85716.75 kcal/mol to -87927.80 kcal/mol (Fig. 5c). The initial and the final RMS gradient and other details of both the proteins and the complex are mentioned in the energy minimization tables (Supplementary Table S3-S5). From the time vs temperature plot, it is clear that the EISvac chimeric vaccine stabled at 301.171K (Fig. 6a), the TLR-4 protein stabled at 300.407K (Fig. 6b) and the complex (TLR-4+EISvac) stabled at 299.427K (Fig. 6c).

After MDS, trajectory analysis to know the changes in the RMSD values and RMSF were analyzed using Discovery Studio client 2017. The RMSD of the chimeric vaccine (EISvac) for 100 conformations was around 1.3 (Fig. 7a) A slight change in the RMSD was observed between the TLR-4 and the complex (Fig. 7b). This indicates that binding of chimeric vaccine with the TLR-4 results in changes to the RMSD of the TLR-4 amino acids. The analysis of RMSF results of the chimeric vaccine and revealed that after binding, there are fluctuation. Fluctuations in the root mean square in the amino acid residues of the ligand molecule (EISvac) before and after docking with TLR-4 receptor (Fig. 8a) and TLR-4 receptor amino acids were also observed (Fig. 8b). These fluctuations are responsible for the conformational changes of the binding proteins. The final results of MDS concludes that the binding of EISvac chimeric vaccine with
TLR-4 induces the immune response and the final conformational changes may attribute to immunomodulation.

**Conclusion**

TB remains among the top 10 causes of death worldwide. Mtb, the pathogen that causes TB keeps evolving, thereby evading the host immune response. The development of MDR-TB and XDR-TB has further weakened the battle against eradication of TB. Thus, it was deemed significant to develop a multi-epitope vaccine candidate, capable of eliciting a strong immune response. In the present study, Immunoinformatics and immunological approaches were used to design a chimeric vaccine construct against TB. Highly antigenic epitopes of B-cell, CTL and HTL epitopes were predicted and used to construct the vaccines so that it is capable of inducing innate, cell mediated and humoral immunity. The molecular docking studies revealed that around 33 different interaction are involved in binding of the chimeric vaccine with TLR-4. Among the interaction, 17 hydrogen bonds and 3 salt bridges were identified. Among the non-covalent interactions, hydrogen bond and salt bridge are very strong interactions. Thus, it can be concluded that the interaction between the chimeric vaccine and TLR-4 was stable. [62–64]. The stability of the chimeric vaccine was confirmed by MDS and the interaction of the chimeric vaccine with the immune receptor, TLR 4 was found to be stable. Thus, this predicted chimeric vaccine candidate can be further validated by in vitro and in vivo methods.

**Declarations**

**Funding:** Not applicable.

**Conflicts of interest/Competing interests:** The authors declare no competing interests.

**Availability of data and material:** Not applicable

**Code availability:** Not applicable

**Authors’ contributions**

NA and SJ are conceived and designed the methodology and research. LR conducted the experiments and analyzed the data. LR and LV wrote the manuscript and analyzed the final results. All the authors read and approved the manuscript.

**Ethics approval:** Not applicable.

**Consent to participate:** Not applicable.

**Consent for publication:** Not applicable.

**Acknowledgements:**
Logesh Radhakrishnan thanks ICMR, New Delhi, for providing SRF fellowship under ICMR-SRF scheme (F.No. 2020-0056/CMB-BMS dated 12/02/2021). The authors thanks B.S.A.Crescent Institute of Science and Technology for the moral support and providing the laboratory facilities.

References

1. Harding, E. WHO global progress report on tuberculosis elimination. ed. Lancet Respir Med. 2020 Jan;8(1):19. doi: 10.1016/S2213-2600(19)30418-7. Epub 2019 Nov 6.

2. Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemka, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., Peloquin, C. A., Raftery, A., Saukkonen, J., Schaaf, H. S., Sotgiu, G., Starke, J. R., Migliori, G. B. & Vernon, A. (2016). Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 63(7), e147-e195.

3. Xia, Y., Zhou, Y., Carter, D. S., McNeil, M. B., Choi, W., Halladay, J., Berry, P. W., Mao, W., Hernandez, V., O’Malley, T., Korkegian, A., Sunde, B., Flint, L., Woolhiser, L. K., Scherman, M. S., Gruppo, V., Hastings, C., Robertson, G. T., Ioerger, T. R., Sacchettini, J., Tonge, P. J., Lenaerts, A. J., Parish, T. & Alley, M. (2018). Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA. Life Sci Alliance, 1(3), e201800025-e201800025.

4. Robertson, G. T., Ektnitphong, V. A., Scherman, M. S., McNeil, M. B., Dennison, D., Korkegian, A., Smith, A. J., Halladay, J., Carter, D. S., Xia, Y., Zhou, Y., Choi, W., Berry, P. W., Mao, W., Hernandez, V., Alley, M. R. K., Parish, T. & Lenaerts, A. J. (2019). Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model. Antimicrob Agents Chemotherapy, 63(4), e02071-02018.

5. Kumar, K. & Kon, O. M. (2017). Diagnosis and treatment of tuberculosis: latest developments and future priorities. Annals of Research Hospitals, 1(5).

6. Ravesloot-Chávez, M. M., Dis, E. V. & Stanley, S. A. (2021). The Innate Immune Response to Mycobacterium tuberculosis Infection. Annual Review of Immunology, 39(1), 611-637.

7. Cavalcanti, Y. V. N., Brelaz, M. C. A., Neves, J. K. d. A. L., Ferraz, J. C. & Pereira, V. R. A. (2012). Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulmonary Medicine, 2012, 745483.

8. Raja, A. (2004). Immunology of tuberculosis. The Indian journal of medical research, 120, 213-232.

9. Day, T. A., Mittler, J. E., Nixon, M. R., Thompson, C., Miner, M. D., Hickey, M. J., Liao, R. P., Pang, J. M., Shayakhmetov, D. M. & Sherman, D. R. (2014). Mycobacterium tuberculosis strains lacking surface lipid
phthiocerol dimycocerosate are susceptible to killing by an early innate host response. Infection and Immunity, 82, 5214-5222.

10. du Plessis, W. J., Walzl, G. & Loxton, A. G. (2016). B cells as multi-functional players during Mycobacterium tuberculosis infection and disease. Tuberculosis, 97, 118-125.

11. Maglione, P. J. & Chan, J. (2009). How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol, 39(3), 676-686.

12. Lund, F. E. & Randall, T. D. (2010). Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol, 10(4), 236-247.

13. Matucci, A., Maggi, E. & Vultaggio, A. (2014). Cellular and Humoral Immune Responses During Tuberculosis Infection: Useful Knowledge in the Era of Biological Agents. The Journal of Rheumatology, 91, 17.

14. Hoft, S. G., Sallin, M. A., Kauffman, K. D., Sakai, S., Ganusov, V. V. & Barber, D. L. (2019). The Rate of CD4 T Cell Entry into the Lungs during Mycobacterium tuberculosis Infection Is Determined by Partial and Opposing Effects of Multiple Chemokine Receptors. Infection and Immunity, 87(6), e00841-00818.

15. Khan, T. A., Mazhar, H., Saleha, S., Tipu, H. N., Muhammad, N. & Abbas, M. N. (2016). Interferon-Gamma Improves Macrophages Function against M. tuberculosis in Multidrug-Resistant Tuberculosis Patients. Chemotherapy research and practice, 2016, 7295390-7295390.

16. Domingo-Gonzalez, R., Prince, O., Cooper, A. & Khader, S. A. (2016). Cytokines and Chemokines in Mycobacterium tuberculosis Infection. Microbiology spectrum, 4(5), 10.1128/microbiolspec.TBTB1122-0018-2016.

17. Romero-Adrian, T. B. (2015). Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. World Journal of Immunology, 5(1).

18. Chai, Q., Wang, L., Liu, C. H. & Ge, B. (2020). New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cellular & Molecular Immunology, 17(9), 901-913.

19. Olsen, A., Chen, Y., Ji, Q., Zhu, G., De Silva, A. D., Vilchève, C., Weisbrod, T., Li, W., Xu, J., Larsen, M., Zhang, J., Porcelli, S. A., Jacobs, W. R. & Chan, J. (2016). Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines. mBio, 7(3), e01023-01015.

20. Wei, J., Dahl, J. L., Moulder, J. W., Roberts, E. A., O'Gaora, P., Young, D. B. & Friedman, R. L. (2000). Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J Bacteriol, 182(2), 377-384.
21. Green, K. D., Chen, W. & Garneau-Tsodikova, S. (2012). Identification and Characterization of Inhibitors of the Aminoglycoside Resistance Acetyltransferase Eis from Mycobacterium tuberculosis. ChemMedChem, 7(1), 73-77.

22. Pan, Q., Zhao, F.-L. & Ye, B.-C. (2018). Eis, a novel family of arylalkylamine N-acetyltransferase (EC 2.3.1.87). Scientific Reports, 8(1), 2435.

23. Duan, L., Yi, M., Chen, J., Li, S. & Chen, W. (2016). Mycobacterium tuberculosis EIS gene inhibits macrophage autophagy through up-regulation of IL-10 by increasing the acetylation of histone H3. Biochemical and Biophysical Research Communications, 473(4), 1229-1234.

24. Samuel, L. P., Song, C.-H., Wei, J., Roberts, E. A., Dahl, J. L., Barry, C. E., Jo, E.-K. & Friedman, R. L. (2007). Expression, production and release of the Eis protein by Mycobacterium tuberculosis during infection of macrophages and its effect on cytokine secretion. Microbiology (Reading), 153(2), 529-540.

25. Bahrami, A. A., Payandeh, Z., Khalili, S., Zakeri, A. & Bandehpour, M. (2019). Immunoinformatics: In Silico Approaches and Computational Design of a Multi-epitope, Immunogenic Protein. International Reviews of Immunology, 38(6), 307-322.

26. Khalili, S., Jahangiri, A., Borna, H., Ahmadi Zanoos, K. & Amani, J. (2014). Computational vaccinology and epitope vaccine design by immunoinformatics. Acta Microbiol Immunol Hung, 61(3), 285-307.

27. Fieser, T. M., Tainer, J. A., Geysen, H. M., Houghten, R. A. & Lerner, R. A. (1987). Influence of protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix. Proceedings of the National Academy of Sciences of the United States of America, 84(23), 8568-8572.

28. Emini, E. A., Hughes, J. V., Perlow, D. S. & Boger, J. (1985). Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. Journal of virology, 55(3), 836-839.

29. Karplus, P. A. & Schulz, G. E. (1985). Prediction of chain flexibility in proteins. Naturwissenschaften, 72(4), 212-213.

30. Kolaskar, A. S. & Tongaonkar, P. C. (1990). A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Letters, 276(1-2), 172-174.

31. Parker, J. M. R., Guo, D. & Hodges, R. S. (1986). New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and x-ray-derived accessible sites. Biochemistry, 25(19), 5425-5432.

32. Ponomarenko, J., Bui, H.-H., Li, W., Fusseder, N., Bourne, P. E., Sette, A. & Peters, B. (2008). ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics, 9(1), 514.
33. Larsen, J. E. P., Lund, O. & Nielsen, M. (2006). Improved method for predicting linear B-cell epitopes. Immunome Res, 2, 2-2.

34. Tenzer, S., Peters, B., Bulik, S., Schoor, O., Lemmel, C., Schatz, M. M., Kloetzel, P. M., Rammensee, H. G., Schild, H. & Holzhütter, H. G. (2005). Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cellular and Molecular Life Sciences CMLS, 62(9), 1025-1037.

35. Calis, J. J. A., Maybeno, M., Greenbaum, J. A., Weiskopf, D., De Silva, A. D., Sette, A., Keşmir, C. & Peters, B. (2013). Properties of MHC Class I Presented Peptides That Enhance Immunogenicity. PLOS Computational Biology, 9(10), e1003266.

36. Dimitrov, I., Garnev, P., Flower, D. R. & Doytchinova, I. (2010). MHC Class II Binding Prediction-A Little Help from a Friend. Journal of biomedicine & biotechnology, 2010, 705821-705821.

37. Vedamurthy, G. V., Ahmad, H., Onteru, S. K. & Saxena, V. K. (2019). In silico homology modelling and prediction of novel epitopic peptides from P24 protein of Haemonchus contortus. Gene, 703, 102-111.

38. Doytchinova, I. A. & Flower, D. R. (2007). VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics, 8(1), 4.

39. Dimitrov, I., Flower, D. R. & Doytchinova, I. (2013). AllerTOP—a server for in silico prediction of allergens. BMC Bioinformatics, 14 Suppl 6(Suppl 6), S4-S4.

40. Gupta, S., Kapoor, P., Chaudhary, K., Gautam, A., Kumar, R., Open Source Drug Discovery, C. & Raghava, G. P. S. (2013). In Silico Approach for Predicting Toxicity of Peptides and Proteins. PLoS One, 8(9), e73957.

41. Rahmani, A., Baee, M., Rostamtabar, M., Karkhah, A., Alizadeh, S., Tourani, M. & Nouri, H. R. (2019). Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against Schistosoma mansoni using immunoinformatics approaches. International Journal of Biological Macromolecules, 141, 125-136.

42. Dhanda, S. K., Vir, P. & Raghava, G. P. S. (2013). Designing of interferon-gamma inducing MHC class-II binders. Biology Direct, 8(1), 30.

43. Shey, R. A., Ghogomu, S. M., Esoh, K. K., Nebangwa, N. D., Shintouo, C. M., Nongley, N. F., Asa, B. F., Ngale, F. N., Vanhamme, L. & Souopgui, J. (2019). In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. Scientific Reports, 9(1), 4409.

44. Saha, R. & Prasad, B. V. L. S. (2020). Insilico approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2). bioRxiv, 2020.2003.2031.017459.
45. Wang, S., Li, W., Zhang, R., Liu, S. & Xu, J. (2016). CoinFold: a web server for protein contact prediction and contact-assisted protein folding. Nucleic Acids Research, 44(W1), W361-W366.

46. Wang, S., Sun, S., Li, Z., Zhang, R. & Xu, J. (2017). Accurate De Novo Prediction of Protein Contact Map by Ultra-Deep Learning Model. PLOS Computational Biology, 13(1), e1005324.

47. Bhattacharya, D., Nowotny, J., Cao, R. & Cheng, J. (2016). 3Drefine: an interactive web server for efficient protein structure refinement. Nucleic Acids Res, 44(W1), W406-409.

48. Colovos, C. & Yeates, T. O. (1993). Verification of protein structures: patterns of nonbonded atomic interactions. Protein science: a publication of the Protein Society, 2(9), 1511-1519.

49. Pontius, J., Richelle, J. & Wodak, S. J. (1996). Deviations from Standard Atomic Volumes as a Quality Measure for Protein Crystal Structures. Journal of Molecular Biology, 264(1), 121-136.

50. Wiederstein, M. & Sippl, M. J. (2007). ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res, 35, 21.

51. Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D. & Bairoch, A. (2003). ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic acids research, 31(13), 3784-3788.

52. Mitaku, S., Hirokawa, T. & Tsuji, T. (2002). Amphiphilicity index of polar amino acids as an aid in the characterization of amino acid preference at membrane-water interfaces. Bioinformatics, 18(4), 608-616.

53. Wilkins, M. R., Gasteiger, E., Bairoch, A., Sanchez, J. C., Williams, K. L., Appel, R. D. & Hochstrasser, D. F. (1999). Protein identification and analysis tools in the ExPASy server. Methods in molecular biology (Clifton, N.J.), 112, 531-552.

54. Haneef, M., Lohani, M., Dhasmana, A., Jamal, Q. M. S., Shahid, S. M. A. & Firdaus, S. (2014). Molecular Docking of Known Carcinogen 4- (Methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) with Cyclin Dependent Kinases towards Its Potential Role in Cell Cycle Perturbation. Bioinformation, 10(8), 526-532.

55. Nanda Kumar, Y., Jeyakodi, G., Gunasekaran, K. & Jambulingam, P. (2016). Computational screening and characterization of putative vaccine candidates of Plasmodium vivax. Journal of biomolecular structure & dynamics, 34(8), 1736-1750.

56. Shan, C., Li, H., Zhang, Y., Li, Y., Chen, Y. & He, W. (2019). Binding interactions of epididymal protease inhibitor and semenogelin-1: a homology modeling, docking and molecular dynamics simulation study. PeerJ, 7, e7329-e7329.

57. Chatterjee, N., Ojha, R., Khatoon, N. & Prajapati, V. K. (2018). Scrutinizing Mycobacterium tuberculosis membrane and secretory proteins to formulate multiepitope subunit vaccine against pulmonary tuberculosis by utilizing immunoinformatic approaches. Int J Biol Macromol, 118(Pt A), 180-188.
58. Puratchikody, A., Irfan, N. & Balasubramaniyan, S. (2019). Conceptual design of hybrid PCSK9 lead inhibitors against coronary artery disease. Biocatalysis and Agricultural Biotechnology, 17, 427-440.

59. Abreu, R., Essler, L., Giri, P. & Quinn, F. (2020). Interferon-gamma promotes iron export in human macrophages to limit intracellular bacterial replication. PLoS One, 15(12), e0240949-e0240949.

60. Ní Cheallaigh, C., Keane, J., Lavelle, E. C., Hope, J. C. & Harris, J. (2011). Autophagy in the immune response to tuberculosis: clinical perspectives. Clin Exp Immunol, 164(3), 291-300.

61. Wang, S., Li, W., Liu, S. & Xu, J. (2016). RaptorX-Property: a web server for protein structure property prediction. Nucleic acids research, 44(W1), W430-W435.

62. Bosshard, H. R., Marti, D. N. & Jelesarov, I. (2004). Protein stabilization by salt bridges: concepts, experimental approaches and clarification of some misunderstandings. J Mol Recognit, 17(1), 1-16.

63. Fu, Y., Zhao, J. & Chen, Z. (2018). Insights into the Molecular Mechanisms of Protein-Ligand Interactions by Molecular Docking and Molecular Dynamics Simulation: A Case of Oligopeptide Binding Protein. Comput Math Methods Med, 4(3502514).

64. Kurczab, R., Śliwa, P., Rataj, K., Kafel, R. & Bojarski, A. J. (2018). Salt Bridge in Ligand–Protein Complexes—Systematic Theoretical and Statistical Investigations. Journal of Chemical Information and Modeling, 58(11), 2224-2238.

**Tables**

Due to technical limitations, table 1-7 is only available as a download in the Supplemental Files section.

**Figures**
Figure 1

a-dB cell epitopes predicted based on the accessibility, antigenicity flexibility and hydrophilicity, using IEDB server Tools.
Figure 2

Refined 3D structure of the predicted vaccine model (EISvac). Tertiary Structure was predicted using RaptorX server, 3D refinement was done by 3Drefine server and the structure was visualized in Discovery studio 2017.
Figure 3

Validation of refined 3D structure of the predicted vaccine model (EISvac). (a) Ramachandran plot analysis reveals that 89.2% of the amino acid residues are in the most favoured region. (b) Z-score of the refined model was found to be -7, as predicted by ProSA-web tool. (c) Overall quality of the modelled protein structure was 98.476, as predicted from the ERRAT tool. (d) Predicted hydrophobic regions of the vaccine model (EISvac) by ProtScale Tool. In the vertical axis positive value indicates that the amino acids residues are hydrophobic and negative values indicate that those residues are hydrophilic in nature.
Figure 4

Visualization of Protein-Protein docking of TLR-4 with the predicted EISvac vaccine model in Discovery studio client 2017. In the surface mode, TLR-4 is represented in pink and the predicted vaccine model (EISvac) is represented in violet.
Figure 5

Molecular dynamic simulation. Time (ps) vs Total energy (kCal/mol) plot of (a) the predicted vaccine model (EISvac), (b) TLR-4 and (c) the complex (TLR-4+EISvac).

Fig. 6
**Figure 6**

Molecular dynamic simulation. Time (ps) vs Temperature (K) plot in Dynamic Simulation. (a) the predicted vaccine model (EISvac), (b) TLR-4 and (c) the complex (TLR-4+EISvac).

**Figure 7**

Trajectory analysis of the predicted vaccine model (EISvac), TLR-4 and Complex (TLR-4+EISvac). (a) RMSD value of 100 conformation of predicted vaccine model (EISvac). (b) RMSD value of 100 conformation of TLR-4 and Complex (TLR-4+EISvac).
Figure 8

Trajectory analysis of both the receptor (TLR-4) and ligand (EISvac) before and after molecular docking. (A) RMSF of amino acid residues of the predicted vaccine model (EISvac) before and after protein-protein docking with TLR-4. (B) RMSF of amino acid residues of the receptor TLR-4 before and after Protein-Protein docking with the predicted vaccine model (EISvac).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarymaterial.docx
- Tables.pdf